Breast hyperplasia
Fibrocystic breast disease is the most common breast disease in women, and its incidence ranks first among breast diseases. In recent years, the incidence of the disease has been increasing year by year, and the age of onset is getting younger and younger. Fibrocystic breast disease is the physiological proliferation and incomplete restoration of normal breast lobules, and the normal structure of the breast is disordered. It is a pathological hyperplasia. It is neither an inflammatory nor a tumor disease. It is more common in women aged 30-50, with the peak incidence at 35-40 years old.
-
Site of disease:
breast -
Infectious :
Not contagious -
Frequent population:
Women aged 30-50 -
Related symptoms:
Breast pain nodule cyst premenstrual breast pain axillary pain -
Concurrent disease:
Related Drugs
Ru Zeng Ning Capsules
Manufacturer:
Shaanxi Jianmin Pharmaceutical Co., Ltd.
Ru Zeng Ning Capsules
Manufacturer:
Bengbu Fengyuan Pharmaceutical Co., Ltd.
Breast core internal solution
Manufacturer:
Beijing Maidihai Medical Business Co., Ltd.
Breast core internal solution
Manufacturer:
Tonghua Golden-Horse Pharmaceutical Industey Co., Ltd.
Rupishu Tablets
Manufacturer:
Pharmaceutical Factory of Shaanxi Provincial Academy of Sciences
Exemestane Tablets
Indication: It is indicated for postmenopausal patients with advanced breast cancer whose disease has progressed after treatment with tamoxifen.
Prunella Vulgaris Paste
Manufacturer:
Wuhan Taifu Pharmaceutical Co., Ltd.
Prunella Vulgaris Paste
Manufacturer:
Sichuancentralpharmaceutical Co., Ltd.
Prunella Vulgaris Paste
Manufacturer:
Chongqing Kerui Donghe Pharmaceutical Co., Ltd.
Related Ingredients
-
Dehydroandrographolide list
134418-28-3 -
Exemestane list
107868-30-4